Imlifidase clinical trials
Also written IdeS and HMED-IdeS.
How each study uses imlifidase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the imlifidase studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 25 Aug 2020 · Idefirix · EMEA/H/C/004849 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 4
Hansa Biopharma AB (12) · Cedars-Sinai Medical Center (1) · Mårten Segelmark (1) · Genethon (1) · Sarepta Therapeutics, Inc. (1) · Fundacion Clinic per a la Recerca Biomédica (1)
Often tested with
Tested in the same studies.
GNT0003 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test imlifidase.
- Feb 2027Imlifidase Prior to Kidney Transplant in Highly Sensitised ChildrenPhase 2 · Hansa Biopharma AB
Studies
Open first, then newest update. How each study uses imlifidase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Imlifidase Prior to Kidney Transplant in Highly Sensitised ChildrenRecruitingPhase 2Hansa Biopharma ABNCT05753930Written as ImlifidaseHow we know
- Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar SyndromeRecruitingPhase 2GenethonNCT06518005Written as ImlifidaseHow we know
- A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)TerminatedPhase 1Sarepta Therapeutics, Inc.NCT06241950Written as imlifidaseHow we know
- A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient GroupActive, not recruitingPhase 3Hansa Biopharma ABNCT05937750Written as Imlifidase administered in the 20-HMedIdeS-19 (PAES) studyHow we know
- Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference CohortsCompletedPhase 3Hansa Biopharma ABNCT05369975Written as ImlifidaseHow we know
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxCompletedPhase 3Hansa Biopharma ABNCT04935177Written as ImlifidaseHow we know
- A Study With Imlifidase in Anti-GBM DiseaseTerminatedPhase 3Hansa Biopharma ABNCT05679401Written as ImlifidaseHow we know
- A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to TransplantationTerminatedPhase 2Hansa Biopharma ABNCT05049850Written as ImlifidaseHow we know
- A Study of Imlifidase in Patients With Guillain-Barré SyndromeCompletedPhase 2Hansa Biopharma ABNCT03943589Written as ImlifidaseHow we know
- Imlifidase in Living Donor Renal Transplantation Highly Sensitized RecipientsWithdrawnPhase 2Fundacion Clinic per a la Recerca BiomédicaNCT06461546Written as ImlifidaseHow we know
- An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant PatientsCompletedPhase 2Hansa Biopharma ABNCT03897205Written as ImlifidaseHow we know
- Ides in Highly Sensitized (HS) Patients Awaiting Kidney TransplantationCompletedPhase 1/2Cedars-Sinai Medical CenterNCT02426684Written as IdeS® (Imlifidase)How we know
- Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM DiseaseCompletedPhase 2Mårten SegelmarkNCT03157037Written as ImlifidaseHow we know
- A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch TestCompletedPhase 2Hansa Biopharma ABNCT02790437Written as IdeSHow we know
- Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney TransplantationCompletedPhase 2Hansa Biopharma ABNCT02475551Written as IdeSHow we know
- Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney DiseaseCompletedPhase 2Hansa Biopharma ABNCT02224820Written as IdeSHow we know
- Safety Study on IdeS in Healthy VolounteersCompletedPhase 1Hansa Biopharma ABNCT01802697Written as IdeSHow we know
Codes
What other systems call imlifidase · ClinicalTrials.gg INT018170
- UNII (FDA) UVJ7NL8S2PIMLIFIDASEConfirmed FDA, Wikidata
- Wikidata Q97353944imlifidaseConfirmed FDA, Wikidata
- NCI Thesaurus C170061ImlifidaseOne source FDA
- DrugBank DB15258One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UVJ7NL8S2P | IMLIFIDASE | Confirmed FDA, Wikidata |
| Wikidata | Q97353944 | imlifidase | Confirmed FDA, Wikidata |
| NCI Thesaurus | C170061 | Imlifidase | One source FDA |
| DrugBank | DB15258 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.